OpenLB
Open Library of Bioscience
Advanced Search
Leukemia research
Dec, 2014;38 (12): 1399-400.

Thinking outside of ABL1 for resistance to tyrosine kinase inhibitors: a perspective of the SEPT9-ABL1 fusion protein.

Tinghui Hu, Bryan T Ciccarelli
Author Information
  1. Tinghui Hu: Department of Microbiology and Molecular Genetics; the New Jersey Medical School-Cancer Center; Rutgers Biomedical and Health Sciences, Newark, NJ, USA. Electronic address: th365@njms.rutgers.edu.
  2. Bryan T Ciccarelli: Department of Microbiology and Molecular Genetics; the New Jersey Medical School-Cancer Center; Rutgers Biomedical and Health Sciences, Newark, NJ, USA.
PMID: 25449686 DOI: 10.1016/j.leukres.2014.09.015

Abstract

No abstract text available.

Keywords

ABL1 fusion protein Resistance SEPT9-ABL1 Tyrosine kinase inhibitors

MeSH Term

Humans
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Oncogene Proteins, Fusion
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-abl
Septins

Chemicals

Oncogene Proteins, Fusion
Protein Kinase Inhibitors
Proto-Oncogene Proteins c-abl
SEPTIN9 protein, human
Septins
Editorial

Word Cloud

Created with Highcharts 10.0.0ABL1kinaseSEPT9-ABL1fusionproteinThinkingoutsideresistancetyrosineinhibitors:perspectiveResistanceTyrosineinhibitors

Similar Articles

Cited By